A61K - Preparations for medical, dental, or toilet purposes

More topics under "A61K - Preparations for medical, dental, or toilet purposes" (2,585,043)
A61K 101 - Radioactive non-metals (526)
A61K 103 - Radioactive metals (481)
A61K 125 - Containing or obtained from roots, bulbs, tubers, corms or rhizomes (2,645)
A61K 127 - Containing or obtained from leaves (1,806)
A61K 129 - Containing or obtained from bark (325)
A61K 131 - Containing or obtained from seeds, nuts, fruits or grains (1,932)
A61K 133 - Containing or obtained from flowers or blossoms (665)
A61K 135 - Containing or obtained from stems, stalks, branches, twigs or shoots (756)
A61K 31 - Medicinal preparations containing organic active ingredients (785,912)
A61K 33 - Medicinal preparations containing inorganic active ingredients (56,213)
A61K 35 - Medicinal preparations containing material or reaction products thereof with undetermined constitution (125,838)
A61K 36 - Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines (179,316)
A61K 38 - Medicinal preparations containing peptides (316,240)
A61K 39 - Medicinal preparations containing antigens or antibodies (182,248)
A61K 41 - Medicinal preparations obtained by treating materials with wave energy or particle radiation (9,445)
A61K 45 - Medicinal preparations containing active ingredients not provided for in groups (115,020)
A61K 47 - Medicinal preparations characterised by the non-active ingredients used, e.g. carriers, inert additives (171,128)
A61K 48 - Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy (86,964)
A61K 49 - Preparations for testing in vivo (35,376)
A61K 50 - Electrically conductive preparations for use in therapy or testing in vivo, e.g. conductive adhesives or gels to be used with electrodes for electrocardiography (ecg) or for transcutaneous drug administration (62)
A61K 51 - Preparations containing radioactive substances for use in therapy or testing in vivo (24,291)
A61K 6 - Preparations for dentistry (18,259)
A61K 8 - Cosmetics or similar toilet preparations (170,551)
A61K 9 - Medicinal preparations characterised by special physical form (299,044)

Patents for A61K - Preparations for medical, dental, or toilet purposes (29,449)
12/2004
12/09/2004	US20040247566 Having at least one amino-acid substitution and including multimers and Fc-fusion constructs; treating a human lung disorder such as chronic obstructive pulmonary disorder, asthma, emphysema, and chronic bronchitis
12/09/2004	US20040244122 Containing 2-electron oxidoreductases, electron donors and cationic cellulose or polymer; ready to use; homogeneous, intense, chromatic colorations; does not degrade hair; long lasting, wash resistance
12/09/2004	CA2820174A1 Low sodium solution for dialysis
12/09/2004	CA2527420A1 Compounds, methods and pharmaceutical compositions for inhibiting parp
12/09/2004	CA2527186A1 Compositions comprising gastrin compounds and their use in diabetes
12/09/2004	CA2526383A1 Methods and materials for treating, detecting, and reducing the risk of developing alzheimer's disease
12/09/2004	CA2525865A1 Antimicrobial quaternary ammonium organosilane coatings
12/09/2004	CA2524375A1 Topical composition for the treatment of skin disorders and methods of using the same
12/08/2004	EP1484333A1 New aminopropylphosphonous acids
12/08/2004	EP1220856B1 Pyrazolo[4,3-d]pyrimidine derivatives
12/08/2004	EP0952836B1 Use of sulphoquinovosyldiacylglycerols for the treatment of inflammatory skin diseases
12/08/2004	CN1553895A Taxol enhancer compounds
12/08/2004	CN1553894A Taxol enhancer compounds
12/08/2004	CN1553815A Pharmaceutical formulation for the intramuscular administration of fulvestrant
12/08/2004	CN1553801A Inhalation compositions comprising tricyclic 5,6-dihydro-9H-pyrazolo (3,4-C)-1,2,4-triazolo (4,3-alpha) pyridines
12/08/2004	CN1552322A Pharmaceutical compositions of tizoxanide and nitazoxanide
12/08/2004	CN1178955C Modified TNF alpha molecules and DNA encoding such modified TNF alpha molecules and vaccines comprising such modified TNF alpha molecules and DNA
12/08/2004	CN1178939C Non-nucleoside reverse transcriptase inhibitors
12/08/2004	CN1178697C Infectious bursits vaccine
12/08/2004	CN1178652C Mizoribine tablet with improved colour
12/08/2004	CN1178642C Oral care compositions
12/07/2004	US6828445 Process for the preparation of baccatin III derivatives
12/07/2004	US6828315 1-Amino triazoloc4,3-a! quinazoline-5-ones and/or -5-thiones inhibiting phosphodiesterase IV
12/07/2004	US6827945 First ingredient obtainable from turmeric; a second ingredient obtainable from ginger; and a third ingredient obtainable from horseradish; treating viral infections
12/07/2004	US6827712 Robotic arm DLUs for performing surgical tasks
12/07/2004	CA2352332C Hygromycin a derivatives
12/02/2004	WO2004104007A1 Pyrazolo-quinazoline derivatives,process for their preparation and their use as kinase inhibitors
12/02/2004	WO2004103317A2 Transdermal buprenorphine dosage regimen for treatment of diarrhea
12/02/2004	WO2004103316A2 Orp9, a novel therapeutic target for increasing hdl levels
12/02/2004	WO2004103314A2 Polyol polyester-containing personal care products that do not contain low viscosity silicone fluids
12/02/2004	WO2004103313A2 Methods of reducing vascular permeability in tissue by inhibition of tissue plasminogen activator (tpa) and tpa inhibitors useful therein
12/02/2004	WO2004103312A2 Peptides useful as hiv fusion inhibitors
12/02/2004	WO2004103311A2 Antibiotic composition
12/02/2004	WO2004103310A2 Methods and compositions for the treatment of metabolic disorders
12/02/2004	WO2004103309A2 Immunosuppressant compounds and compositions
12/02/2004	WO2004103307A2 Method of use of five and fifteen carbon fatty acids
12/02/2004	WO2004103306A2 Immunosuppressant compounds and compositions
12/02/2004	WO2004103305A2 Spiropyrazole compound
12/02/2004	WO2004103304A2 Treatment of t-cell mediated diseases
12/02/2004	WO2004103303A2 Therapeutic dental composition
12/02/2004	WO2004103301A2 Synergistic treatment of cancer using immunomers in conjunction with chemotherapeutic agents
12/02/2004	WO2004103300A2 Compositions and methods of treating reduced blood flow to the cns with cox-2 inhibitors and cholinergic agents
12/02/2004	WO2004103299A2 Compositions and methods for the treatment of cns injuries
12/02/2004	WO2004103298A2 Apparatus and method for the treatment of infectious disease in keratinized tissue
12/02/2004	WO2004103297A2 Combination therapy with glatiramer acetate and mitoxantrone for the treatment of multiple sclerosis
12/02/2004	WO2004103296A2 Methods of treating idiopathic pulmonary fibrosis
12/02/2004	WO2004103295A2 Interleukin-9 antagonist muteins and their pharmacological methods of use
12/02/2004	WO2004103294A2 Methods and compositions for the prevention and treatment of sepsis
12/02/2004	WO2004103293A2 Modulators of the p2y10 receptor useful in altering t lymphocyte function
12/02/2004	WO2004103291A2 Extended release compositions of proton pump inhibitor
12/02/2004	WO2004103289A2 Driverse thyroid hormone receptor antagonists and uses thereof
12/02/2004	WO2004103288A2 Method of preventing recurrent miscarriages
12/02/2004	WO2004103287A2 B-arrestin-2 modulation in the treatment of allergic asthma
12/02/2004	WO2004103286A2 Compositions of a cyclooxygenase-2 selective inhibitor and a cholimergic agent
12/02/2004	WO2004103285A2 Lactoferrin in the treatment of diabetes mellitus
12/02/2004	WO2004103284A2 Compositions of a benzenesulfonamide or methylsulfonylbenzene cyclooxygenase-2 selective inhibitor and a cholinergic agent for the treatment of reduced blood flow or trauma to the central nervous system
12/02/2004	WO2004103283A2 Compositions of a cyclooxygenase-2 selective inhibitor and a central nervous system stimulant for the treatment of central nervous system damage
12/02/2004	WO2004103282A2 Compounds, compositions and methods
12/02/2004	WO2004103281A2 Vanilloid receptor antagonists, and methods of making and using them
12/02/2004	WO2004103280A2 Seaweed extract composition for treatment of diabetes and diabetic complications
12/02/2004	WO2004103279A2 3-(2-amino-1-azacyclyl)-5-aryl-1,2,4-oxadiazoles as s1p receptor agonists
12/02/2004	WO2004103278A2 Acyl sulfonamides as inhibitors of hiv integrase
12/02/2004	WO2004103276A2 3-amino-4-phenylbutanoic acid derivatives as dipeptidyl peptidase inhibitors for the treatment or prevention of diabetes
12/02/2004	WO2004103275A2 Compositions and methods for the preparation of human growth hormone glycosylation mutants
12/02/2004	WO2004103271A2 Disease prevention and vaccination prior to thymic reactivations
12/02/2004	WO2004103270A2 Compounds and methods for treatment of thrombosis
12/02/2004	WO2004103269A2 Methods and compositions for vaccination comprising nucleic acid and/or polypeptide sequences of the genus borrelia
12/02/2004	WO2004103268A2 Intracellular production of specific rna molecules by splicing
12/02/2004	WO2004103266A2 Protein kinase c peptides for use in withdrawal
12/02/2004	WO2004103265A2 Whitening and antioxidative cosmetic composition containing resveratrol and method for preparing the same
12/02/2004	WO2004103264A2 Hemostatic antibacterial composition and products incorporating the same
12/02/2004	WO2004103263A2 Dopamine and agonists and antagonists thereof for treatment of neurodegenerative diseases
12/02/2004	WO2004103262A2 Dopamine and agonists and antagonists thereof for modulation of suppressive activity of cd4+cd25+ regulatory t cells
12/02/2004	WO2004103260A2 Ternary and quaternary eutectic mixtures.
12/02/2004	WO2004089281A3 Novel polymorphs of tolterodine tartrate
12/02/2004	WO2004082624A3 Modafinil-based neurorehabilitation of impaired neurological function associated with injury
12/02/2004	WO2004082587A3 Stable lamotrigine pharmaceutical compositions and processes for their preparation
12/02/2004	WO2004080396A3 Liposomal curcumin for treatment of cancer
12/02/2004	WO2004080386A3 Optimization of bacterial sucab expression by promoter mutagenesis for efficient l-glutamic acid production
12/02/2004	WO2004073653A8 Methods for treating pain by administering a nerve growth factor antagonist and an nsaid and compositions containing the same
12/02/2004	WO2004073635A3 Compositions comprising a plurality of particles or agglomerates having a defined particle size
12/02/2004	WO2004071431A3 Method and composition for treating neurodegenerative disorders
12/02/2004	WO2004069147A3 System for enhanced chemical debridement
12/02/2004	WO2004066952A3 Benzoxazole, benzothiazole, and benzimidazole derivatives for the treatment of cancer and other diseases
12/02/2004	WO2004064779A3 Use of nitroglycerin to relieve nocturnal muscle cramps
12/02/2004	WO2004060321A3 Cardioprotective delta opioid receptor agonists and methods of using same
12/02/2004	WO2004050027A3 Materials and methods for treating ocular-related disorders
12/02/2004	WO2004041198A3 Heat pasteurized liquids containing glucosamine
12/02/2004	WO2004037198A3 Antibody-mediated induction of tumor cell death
12/02/2004	WO2004034993A3 Methods of preventing morbidity and mortality by perioperative administration of a blood clotting inhibitor
12/02/2004	WO2004024074A3 Fused heterobicyclo substituted phenyl metabotropic glutamate-5 modulators
12/02/2004	US20040243109 Robotic arm DLUs for performing surgical tasks
12/02/2004	US20040243010 Use of BNP during stress testing for the detection and risk stratification of individuals with suspected coronary artery disease
12/02/2004	US20040242770 Covalent and non-covalent crosslinking of hydrophilic polymers and adhesive compositions prepared therewith
12/02/2004	US20040242704 Administering to the vertebrate an opsin-binding synthetic retinoid in a pharmaceutically acceptable vehicle for restoring photoreceptor function in a vertebrate eye
12/02/2004	US20040242696 Anticancer agent having a quinone, quinone prodrug, catechol or catechol prodrug moiety; free of combretastatin A-1
12/02/2004	US20040242627 2-Iminoimidazole derivatives (1)
12/02/2004	US20040242618 Anticancer agents for prevention of cancer as agonist and antiandrogens
12/02/2004	US20040242617 Combination of selected opioids with muscarine antagonists for treating urinary incontinence
12/02/2004	US20040242606 Anti-cancer cyclopenta (g)quinazoline compounds

1 ... 140 141 142 143 144 145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 ... 295